Xiaoling Xiong

US Patent:

20100184652, Jul 22, 2010

Filed:

Nov 29, 2006

Appl. No.:

12/095728

Inventors:

Leszek Kotula - Marlboro NJ, US
Xiaoling Xiong - Fresh Meadows NY, US

International Classification:

A61K 38/16
C07K 7/08
C07K 14/00
C07K 17/00
A61K 38/10
A61P 35/00

US Classification:

514 12, 530327, 530324, 530350, 514 14

Abstract:

Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue (10) is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an Abl kinase. Further provided are methods of inhibiting an Abl kinase. Also provided are methods of treating a patient having a condition characterized by a mutant AbI kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant AbI kinase. Methods of labeling an AbI kinase are also provided. Additionally, methods of isolating an Abl kinase from a tissue are provided.

US Patent:

20120190045, Jul 26, 2012

Filed:

Mar 7, 2012

Appl. No.:

13/414422

Inventors:

Leszek Kotula - Marlboro NJ, US
Xiaoling Xiong - Fresh Meadows NY, US

Assignee:

NEW YORK BLOOD CENTER, INC. - New York NY

International Classification:

G01N 33/53

US Classification:

435 78

Abstract:

Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue () is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an Abl kinase. Further provided are methods of inhibiting an Abl kinase. Also provided are methods of treating a patient having a condition characterized by a mutant Abl kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant Abl kinase. Methods of labeling an Abl kinase are also provided. Additionally, methods of isolating an Abl kinase from a tissue are provided.